Profile data is unavailable for this security.
About the company
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
- Revenue in USD (TTM)62.30m
- Net income in USD-5.34m
- Incorporated2006
- Employees101.00
- LocationFortress Biotech Inc1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS 33154United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (781) 652-4545
- Websitehttps://www.fortressbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pelthos Therapeutics Inc | 7.41m | -23.58m | 68.09m | 4.00 | -- | 1.17 | -- | 9.19 | -17.09 | -17.09 | 6.02 | 18.85 | 0.1152 | -- | -- | 1,851,500.00 | -36.68 | -- | -47.05 | -- | 68.73 | -- | -318.41 | -- | 1.04 | -12.32 | 0.00 | -- | -- | -- | -7.78 | -- | -- | -- |
| MindWalk Holdings Corp | 15.04m | -22.83m | 69.57m | 102.00 | -- | 5.27 | -- | 4.63 | -0.6343 | -0.6159 | 0.3527 | 0.2826 | 0.4745 | 6.67 | 4.50 | -- | -72.01 | -32.32 | -90.53 | -36.45 | 58.50 | 55.79 | -151.78 | -100.97 | 4.09 | -23.68 | 0.17 | -- | 0.0082 | 11.77 | -11.25 | -- | 10.37 | -- |
| Pliant Therapeutics Inc | 0.00 | -175.50m | 70.67m | 171.00 | -- | 0.3528 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| Scilex Holding Co | 40.36m | -375.84m | 72.69m | 30.00 | -- | -- | -- | 1.80 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
| Assertio Holdings Inc | 137.35m | -28.92m | 76.68m | 58.00 | -- | 0.7248 | 34.74 | 0.5583 | -4.71 | -4.71 | 20.93 | 16.49 | 0.4611 | 1.35 | 1.47 | 2,368,138.00 | -9.71 | -15.74 | -17.07 | -24.19 | 68.16 | 82.29 | -21.06 | -42.01 | 1.43 | -- | 0.2702 | -- | -17.83 | -11.45 | 93.50 | -- | -- | -- |
| Polypid Ltd | 0.00 | -34.22m | 76.85m | 57.00 | -- | 5.00 | -- | -- | -2.98 | -2.98 | 0.00 | 0.9237 | 0.00 | -- | -- | 0.00 | -147.37 | -90.05 | -241.51 | -109.86 | -- | -- | -- | -- | -- | -22.38 | 0.1359 | -- | -- | -- | -21.61 | -- | -38.71 | -- |
| NovaBay Pharmaceuticals Inc | 2.83m | -7.95m | 85.80m | 14.00 | -- | -- | -- | 30.32 | -1.58 | 0.5377 | 0.555 | 0.2718 | 0.7686 | -- | 5.28 | 202,142.90 | -215.92 | -61.58 | -404.37 | -83.79 | 54.56 | 59.49 | -280.92 | -77.39 | -- | -91.56 | 0.0836 | -- | -33.58 | 8.19 | 48.52 | -- | -20.59 | -- |
| Verrica Pharmaceuticals Inc | 30.83m | -26.01m | 90.98m | 71.00 | -- | -- | -- | 2.95 | -3.44 | -3.44 | 3.50 | -1.80 | 0.8352 | 1.09 | 8.75 | 434,211.30 | -70.48 | -71.91 | -217.79 | -111.91 | 91.36 | -- | -84.38 | -729.00 | 1.18 | -1.70 | 1.94 | -- | 47.66 | -- | -14.31 | -- | -47.58 | -- |
| Biostem Technologies Inc | 235.17m | 20.20m | 92.31m | 67.00 | 6.10 | 1.84 | 4.52 | 0.3925 | 0.9019 | 0.9019 | 11.60 | 2.98 | 2.82 | 2.61 | 4.65 | -- | 24.25 | -- | 55.07 | -- | 97.33 | -- | 8.59 | -- | 4.09 | -- | 0.0566 | -- | 1,708.93 | -- | 475.86 | -- | -- | -- |
| Alpha Cognition Inc | 7.43m | -19.47m | 113.28m | 52.00 | -- | 2.50 | -- | 15.25 | -1.37 | -1.37 | 0.5002 | 2.09 | 0.2894 | -- | 5.22 | 142,830.80 | -75.87 | -119.10 | -93.86 | -159.05 | 73.09 | -- | -262.18 | -- | 6.03 | -7.91 | 0.00 | -- | -- | -- | -6.34 | -- | -- | -- |
| Fortress Biotech Inc | 62.30m | -5.34m | 113.91m | 101.00 | -- | 2.04 | -- | 1.83 | -0.293 | -0.293 | 2.16 | 1.80 | 0.4039 | 1.50 | 4.35 | 616,861.40 | -34.90 | -54.95 | -51.59 | -102.13 | 71.56 | 62.39 | -86.41 | -227.71 | 1.97 | -10.63 | 0.4503 | -- | -31.76 | 9.50 | 18.61 | -- | 25.88 | -- |
| Whitehawk Therapeutics Inc | 14.38m | -15.62m | 133.37m | 22.00 | 20.83 | 0.8486 | -- | 9.27 | 0.1358 | 0.1358 | 0.2802 | 3.33 | 0.1138 | 0.5669 | 4.40 | 359,600.00 | -12.36 | -52.97 | -13.76 | -60.63 | 89.22 | -- | -108.58 | -372.67 | 16.76 | -- | 0.00 | -- | 6.69 | -- | 3.15 | -- | 47.49 | -- |
| Karyopharm Therapeutics Inc | 142.53m | -124.62m | 134.95m | 279.00 | -- | -- | -- | 0.9468 | -14.58 | -14.58 | 16.69 | -30.94 | 0.9977 | 1.34 | 4.48 | 510,860.20 | -87.24 | -48.75 | -181.85 | -63.64 | 95.93 | 97.09 | -87.43 | -92.03 | 0.9842 | -2.55 | -- | -- | -0.5451 | 28.85 | 46.60 | -- | -7.17 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 158.40m | 1.00 | -- | 0.8844 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Fortress Biotech Inc's reporting currency: US Dollar USD
10.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 945.46k | 3.05% |
| Summit Financial LLCas of 30 Sep 2025 | 444.75k | 1.43% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 356.18k | 1.15% |
| Shikiar Asset Management, Inc.as of 31 Dec 2025 | 278.47k | 0.90% |
| Geode Capital Management LLCas of 30 Sep 2025 | 244.42k | 0.79% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 220.64k | 0.71% |
| Sculptor Capital LPas of 30 Sep 2025 | 208.90k | 0.67% |
| Kestra Advisory Services LLCas of 30 Sep 2025 | 196.88k | 0.63% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 184.96k | 0.60% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 142.54k | 0.46% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
